IPCA Laboratories Reports Strong Q3FY25 Performance with Revenue Growth
IPCA Laboratories Limited reported strong Q3FY25 results with total revenue of ₹2,392.50 crore and net profit of ₹326.27 crore. For the nine months ended December 31, 2025, the company achieved revenue of ₹7,257.85 crore with net profit of ₹842.05 crore. The results were approved by the Board of Directors on February 13, 2026, demonstrating consistent operational performance and financial growth.

*this image is generated using AI for illustrative purposes only.
IPCA Laboratories Limited has released its unaudited financial results for the quarter and nine months ended December 31, 2025, showcasing steady performance in the pharmaceutical sector. The company's financial metrics reflect consistent operational execution and revenue generation capabilities during the reporting period.
Quarterly Financial Performance
The company's Q3FY25 results demonstrate solid revenue growth and profitability improvements. Total revenue from operations reached ₹2,392.50 crore for the quarter ended December 31, 2025, compared to ₹2,245.37 crore in the corresponding quarter of the previous year.
| Metric: | Q3FY25 | Q3FY24 | Change |
|---|---|---|---|
| Total Revenue: | ₹2,392.50 crore | ₹2,245.37 crore | Higher |
| Net Profit (Before Tax): | ₹428.33 crore | ₹367.92 crore | Improved |
| Net Profit (After Tax): | ₹326.27 crore | ₹248.14 crore | Enhanced |
| Total Comprehensive Income: | ₹363.07 crore | ₹263.72 crore | Increased |
Nine-Month Performance Overview
For the nine months ended December 31, 2025, IPCA Laboratories maintained strong operational momentum with comprehensive financial metrics showing positive trends across key parameters.
| Parameter: | 9M FY25 | 9M FY24 |
|---|---|---|
| Total Revenue: | ₹7,257.85 crore | ₹6,692.90 crore |
| Net Profit (Before Tax): | ₹1,208.68 crore | ₹1,003.14 crore |
| Net Profit (After Tax): | ₹842.05 crore | ₹669.86 crore |
| Total Comprehensive Income: | ₹892.52 crore | ₹704.11 crore |
Earnings Per Share Details
The company's earnings per share metrics for the quarter ended December 31, 2025, stood at ₹12.09 on a basic basis and ₹12.86 on a diluted basis. For the nine-month period, basic earnings per share reached ₹33.63 while diluted earnings per share was ₹33.19.
Corporate Governance and Approvals
The financial results were reviewed by the Audit Committee in their meeting held on February 13, 2026, and subsequently approved by the Board of Directors. The company's statutory auditors have conducted a limited review of these unaudited financial statements, ensuring compliance with regulatory requirements.
Key Financial Highlights
- Share capital remained stable at ₹25.37 crore across all reporting periods
- The company maintained consistent operational performance throughout the nine-month period
- Financial results demonstrate the company's ability to generate sustainable profits and maintain growth trajectory
- Complete detailed financial statements are available on stock exchange websites and the company's official website
The results reflect IPCA Laboratories' continued focus on operational excellence and financial discipline in the competitive pharmaceutical market environment.
Historical Stock Returns for Orient Press
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.26% | -1.66% | -15.79% | -32.63% | -30.55% | -33.28% |





























